Gilead Sciences Inc.

Pharmaceuticals
United States
Executive 1Dr. John C. Martin, Chairman; Chief Executive Officer | Chairman; Chief Executive Officer
Executive 2Dr. John F. Milligan, Ph.D., President; Chief Operating Officer | President;
Earnings Per Share Growth (%)306.08%
Cost of Goods Sold (US$ Millions)$3,788
Current Liabilities (US$ Millions)$5,761
Total Assets (US$ Millions)$17,714
Long Term Debt (Millions)$11,921
Return on Equity106.44%
Revenue (US$ Millions)$24,890
Total Company Assets$34,664
Revenue Growth (%)122.20%
Net Income (US$ Millions)$12,101
Earnings Per Share (US$)$7.35
Total Equity (US$ Millions)$15,426
Profit Margin (%)48.62%
Debt To Equity Ratio (%)0.77%
Inventories (Millions)$1,386